Landmark study sheds light on heart
disease
by NC
(NC)—Doctors know that treatment
with ACE inhibitors reduces the rate of cardiovascular events
(including heart attacks and deaths) among patients at high
risk of such events. Yet no evidence existed to
prove the same benefits in patients with stable disease, who
generally felt well. The EUROPA (European trial on Reduction Of
cardiac events with Perindopril in stable coronary Artery
disease) study set out to find the answer.
In September 2003, results from
this landmark, 24 country trial following 12,218
patients,
were published in the prestigious medical journal, The Lancet.
The EUROPA results showed that patients who took daily doses of
the commonly used ACE inhibitor perindopril (also known as
Coversyl®), in addition to their other preventive medications,
had a 20 per cent reduction in their risk of dying or having a
heart attack. For more information on this milestone study in
cardiology, talk to your doctor or visit
www.europa-trial.org.
- News Canada
About the author:
News Canada
drugs that cause heart
attacks
female heart attacks are
different
first aid for heart
attacks
get rid of panic
attacks
heart attacks and callous
acts
|